Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2020

01-06-2020 | Insulins | Research Letter

Glucagon-like peptide-2 analog and inflammatory state in obese mice

Authors: Sara Baldassano, Antonella Amato, Simona Terzo, Gaetano Felice Caldara, Laura Lentini, Flavia Mulè

Published in: Endocrine | Issue 3/2020

Login to get access

Excerpt

Obesity is characterized by chronic low grade of systemic inflammation that develops in response to nutrient excess and plays a key role in the pathogenesis of insulin resistance. It is characterized by macrophage infiltration into adipose tissue (AT) and abnormal cytokine production. These factors damage the metabolic homeostasis leading to alteration in the insulin signaling in specific tissues and organs such as AT and liver [1]. Thus, obese subjects develop over the time resistance to the cellular actions of insulin. …
Literature
1.
G.S. Hotamisligil, P. Arner, J.F. Caro, R.L. Atkinson, B.M. Spiegelman, Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Investig. 95, 2409–2415 (1995)CrossRef
2.
D.J. Drucker, B. Yusta, Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu. Rev. Physiol. 76, 561–583 (2014)CrossRef
3.
C.P.A. Ivory, L.E. Wallace, D. McCafferty, D.L. Sigalet, Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G1202–G1210 (2008)CrossRef
4.
D.L. Sigalet, L.E. Wallace, J.J. Holst, G.R. Martin, T. Kaji, H. Tanaka, K.A. Sharkey, Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am. J. Physiol. Gastroint. Liver Physiol. 293, G211–G221 (2007)CrossRef
5.
D. Nuzzo, S. Baldassano, A. Amato, P. Picone, G. Galizzi, G.F. Caldara, M. Di Carlo, F. Mulè, Glucagon-like peptide-2 reduces the obesity-associated inflammation in the brain. Neurobiol. Dis. 121, 296–304 (2019)CrossRef
6.
X. Guan, The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 307, R585–R596 (2014)CrossRef
7.
A. Amato, S. Baldassano, F. Mulè, GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity. J. Endocrinol. 229, R57–R66 (2016)CrossRef
8.
P.D. Cani, S. Possemiers, T. Van de Wiele, Y. Guiot, A. Everard, O. Rottier, L. Geurts, D. Naslain, A. Neyrinck, D.M. Lambert, G.G. Muccioli, N.M. Delzenne, Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091–1103 (2009)CrossRef
9.
D. Nuzzo, P. Picone, S. Baldassano, L. Caruana, E. Messina, A. Marino Gammazza, F. Cappello, F. Mulè, M. Di Carlo, Insulin resistance as common molecular denominator linking obesity to Alzheimer’s disease. Curr. Alzheimer Res. 12, 723–735 (2015)CrossRef
10.
S. Baldassano, A. Amato, G.F. Caldara, F. Mulè, Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high fat diet. Endocrine 54, 648–656 (2016)CrossRef
11.
S. Terzo, F. Mulè, G.F. Caldara, S. Baldassano, R. Puleio, M. Vitale, G. Cassata, V. Ferrantelli, A. Amato, Pistachio consumption alleviates inflammation and improves gut microbiota composition in high fat diet fed mice. Int. J. Mol. Sci. 21(1), E365 (2020)CrossRef
12.
S. Baldassano, F. Rappa, A. Amato, F. Cappello, F. Mulè, GLP-2 as beneficial factor in the glucose homeostasis in mice fed a high fat diet. J. Cell. Physiol. 230, 3029–3036 (2015)CrossRef
13.
N. El-Jamal, E. Erdual, M. Neunlist, D. Koriche, C. Dubuquoy, F. Maggiotto, J. Chevalier, D. Berrebi, L. Dubuquoy, E. Boulanger, A. Cortot, P. Desreumaux, Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. Am. J. Physiol. Gastroint. Liver Physiol. 307, G274–G285 (2014)CrossRef
14.
B. Yusta, D. Matthews, J.A. Koehler, G. Pujadas, K.D. Kaur, D.J. Drucker, Localization of glucagon-like peptide-2 receptor expression in the mouse. Endocrinology 8, 1950–1963 (2019)CrossRef
15.
G. Iacobellis, V. Camarena, D.W. Sant, G. Wang, Human epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes. Horm. Metab. Res. 49, 625–630 (2017)CrossRef
16.
N. Ouchi, K. Walsh, Adiponectin as an anti-inflammatory factor. Clin. Chim. Acta 380, 24–30 (2007)CrossRef
17.
S. Xie, B. Liu, S. Fu, W. Wang, Y. Yin, N. Li, W. Chen, J. Liu, D. Liu, GLP-2 suppresses LPS-induced inflammation in macrophages by inhibiting ERK phosphorylation and NF-kappaB activation. Cell. Physiol. Biochem. 34, 590–602 (2014)CrossRef
18.
N. Li, B.W. Liu, W.Z. Ren, J.X. Liu, S.N. Li, S.P. Fu, Y.L. Zeng, S.Y. Xu, X. Yan, Y.J. Gao, D.F. Liu, W. Wang, GLP-2 attenuates LPS-induced inflammation in BV-2 cells by inhibiting ERK1/2, JNK1/2 and NF-κB signaling pathways. Int. J. Mol. Sci. 17, 190 (2016)CrossRef
19.
D. Alvares, S. Hoffman, B. Stankovic, K. Adeli, Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 1864, 326–334 (2019)CrossRef
20.
S. Baldassano, A. Amato, F. Cappello, F. Rappa, F. Mulè, Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet. J. Endocrinol. 217, 11–20 (2013)CrossRef
21.
P. Gual, Y. Le Marchand-Brustel, J.F. Tanti, Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87, 99–109 (2005)CrossRef
Metadata
Title
Glucagon-like peptide-2 analog and inflammatory state in obese mice
Authors
Sara Baldassano
Antonella Amato
Simona Terzo
Gaetano Felice Caldara
Laura Lentini
Flavia Mulè
Publication date
01-06-2020
Publisher
Springer US
Published in
Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02261-0

Other articles of this Issue 3/2020

Endocrine 3/2020 Go to the issue

Original Article

GPR64 promotes cAMP pathway in tumor aggressiveness in sparsely granulated growth hormone cell adenomas

Original Article

Insulin resistance is related with liver fibrosis in type 2 diabetic patients with non-alcoholic fatty liver disease proven biopsy and Mediterranean diet pattern as a protective factor

Research Letter

Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19

Original Article

Atrophy patterns of hippocampal subfields in T2DM patients with cognitive impairment

Meta-Analysis

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials

Mini Review

An update on familial nonmedullary thyroid cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits